Heart scan study sees if new drug clears sticky proteins

NCT ID NCT06073587

Ongoing Disease control Sponsor: Ionis Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether the drug eplontersen can reduce abnormal protein buildup in the heart for people with a condition called ATTR-CM. About 150 participants from a larger trial will get heart scans after 140 weeks of treatment. The goal is to see if the drug helps clear these proteins, which could slow heart damage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR CM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyloidosis cardiomyopathy wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR CM)

Contacts and locations

Show contact details

Locations

Cleveland Clinic Main Campus

Cleveland, Ohio, 44195, United States
Columbia University Irving Medical Center

New York, New York, 10032, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Hospital Universitario Puerta de Hierro

Majadahonda, 28222, Spain
Oregon Health and Science University

Portland, Oregon, 97239, United States